within Pharmacolibrary.Drugs.N_NervousSystem.N06D_AntiDementiaDrugs.N06DA02_Donepezil;

model Donepezil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.99,
    Cl = 2.5277777777777778e-06,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.0121,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0032166666666666667,
    Tlag = 600,
    Vdp = 0.0079,
    k12 = 4.4722222222222223e-07,
    k21 = 4.4722222222222223e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Donepezil</td></tr><tr><td>ATC code:</td><td>N06DA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.13</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Donepezil is an acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease by increasing levels of acetylcholine in the brain. It is approved and widely used today as a first-line medication for mild to moderate dementia of the Alzheimer's type.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of 5 mg donepezil.</p><h4>References</h4><ol><li><p>Choi, HY, et al., &amp; Lim, HS (2015). Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. <i>European journal of clinical pharmacology</i> 71(8) 967–977. DOI:<a href=\"https://doi.org/10.1007/s00228-015-1875-2\">10.1007/s00228-015-1875-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26014587/\">https://pubmed.ncbi.nlm.nih.gov/26014587</a></p></li><li><p>Khwarg, J, et al., &amp; Chung, JY (2024). Population Pharmacokinetic Modeling and Simulation for Dose Optimization of GB-5001, a Long-Acting Intramuscular Injection of Donepezil, in Healthy Participants. <i>Neurology and therapy</i> 13(5) 1453–1466. DOI:<a href=\"https://doi.org/10.1007/s40120-024-00643-4\">10.1007/s40120-024-00643-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39126603/\">https://pubmed.ncbi.nlm.nih.gov/39126603</a></p></li><li><p>Jung, W, et al., &amp; Yun, HY (2022). Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. <i>Pharmaceutics</i> 14(2) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14020244\">10.3390/pharmaceutics14020244</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35213976/\">https://pubmed.ncbi.nlm.nih.gov/35213976</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06DA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Donepezil;
